Korea United Pharm

Cilostazol antiplatelet improved new drug whose dual controlled-release system releases the drug at a steady rate to reduce headache; it remained a leading product in the first half of 2026.

Mosapride citrate improved new drug for functional dyspepsia, built with immediate- and extended-release layers for once-daily dosing.

Hydroxyurea anticancer drug supplied under contracts with Malaysian government hospitals and a Vietnamese partner.

Manufacturing plant in Jeondong-myeon, Sejong City, which renewed its Ukrainian GMP certification under EU-based standards in 2026.

Its research institute, founded in 1994, works on controlled-release formulations, combination drugs, bioavailability enhancement and QbD-based new dosage forms, including inhalants, long-acting injectables and seamless capsules.

Signed a USD 2.2 million contract, through Malaysian importer-distributor Eucogen Sdn Bhd, to supply Hydrin Capsule 500mg to Malaysian government hospitals for three years from 1 October 2026; it is the company's first multi-year government hospital contract in Malaysia.

The Sejong plant renewed its Ukrainian GMP certification under EU-based standards.

At GBPP 2026 (21–22 October, KINTEX) it signed export contracts with Qualimed Pharma in the Philippines for USD 2.5 million of several anticancer products and with Dai Nam Ha Noi in Vietnam for USD 0.77 million of Hydrin Capsule.